CNCE Concert Pharmaceuticals, Inc. Stock Quote

CNCE [NASD]

Index	-	P/E	-	EPS (ttm)	-2.58	Insider Own	3.90%	Shs Outstand	32.68M	Perf Week	-3.65%
Market Cap	207.77M	Forward P/E	-	EPS next Y	-2.77	Insider Trans	-2.45%	Shs Float	25.20M	Perf Month	-36.96%
Income	-72.90M	PEG	-	EPS next Q	-0.69	Inst Own	78.40%	Short Float	2.32%	Perf Quarter	-41.95%
Sales	7.90M	P/S	26.30	EPS this Y	-20.40%	Inst Trans	10.47%	Short Ratio	1.31	Perf Half Y	-30.60%
Book/sh	4.01	P/B	1.65	EPS next Y	19.00%	ROA	-	Target Price	-	Perf Year	-30.23%
Cash/sh	4.19	P/C	1.58	EPS next 5Y	-	ROE	-	52W Range	5.47 - 13.50	Perf YTD	-47.78%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-55.30%	52W High	-49.04%	Beta	0.63
Dividend %	-	Quick Ratio	14.00	Sales past 5Y	-34.70%	Gross Margin	-	52W Low	25.78%	ATR	0.59
Employees	70	Current Ratio	14.00	Sales Q/Q	-46.20%	Oper. Margin	-	RSI (14)	34.88	Volatility	6.04% 7.06%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.68	Prev Close	6.60
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Feb 25 BMO	Payout	-	Avg Volume	445.24K	Price	6.88
Recom	1.80	SMA20	-2.86%	SMA50	-30.46%	SMA200	-32.76%	Volume	134,843	Change	4.24%

Dec-16-20

Initiated

Berenberg

Buy

$25

Mar-30-20

Initiated

Jefferies

Buy

$23

Oct-03-19

Reiterated

H.C. Wainwright

Buy

$29 → $25

Jun-24-19

Initiated

SunTrust

Buy

$30

Jun-13-19

Upgrade

Janney

Neutral → Buy

Jun-13-19

Reiterated

H.C. Wainwright

Buy

$26 → $29

Sep-13-18

Initiated

Janney

Neutral

Mar-09-18

Upgrade

Mizuho

Neutral → Buy

$23 → $27

Jan-12-18

Downgrade

Mizuho

Buy → Neutral

$23

Oct-26-17

Initiated

Mizuho

Buy

$23

Jul-24-17

Initiated

H.C. Wainwright

Buy

$20

Mar-07-17

Reiterated

Stifel

Buy

$21 → $31

Jul-01-16

Initiated

Stifel

Buy

$23

Sep-22-15

Reiterated

ROTH Capital

Buy

$22 → $32

Aug-12-15

Initiated

Brean Capital

Buy

$21

Nov-12-14

Reiterated

ROTH Capital

Buy

$28 → $21

Mar-10-14

Initiated

UBS

Buy

$25

Mar-02-21 07:00AM	Concert Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire
Feb-25-21 03:30PM	Concert Pharmaceuticals, Inc. (CNCE) Q4 2020 Earnings Call Transcript Motley Fool
07:00AM	Concert Pharmaceuticals Reports 2020 Financial Results and Provides Update on Clinical Programs Business Wire
06:30AM	Concert Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Feb-24-21 02:38AM	We Think Concert Pharmaceuticals (NASDAQ:CNCE) Needs To Drive Business Growth Carefully Simply Wall St.
Feb-18-21 07:00AM	Concert Pharmaceuticals to Report Full Year 2020 Results on February 25, 2021 Business Wire
Feb-01-21 03:47PM	Why Concert Pharmaceuticals Stock Cratered Today Motley Fool -28.32%
07:00AM	Concert Pharmaceuticals Announces Results from CTP-692 Phase 2 Trial in Patients with Schizophrenia Business Wire
Dec-30-20 09:00AM	Concert Pharmaceuticals Could Rally in 2021 TheStreet.com
Dec-17-20 01:25PM	Is CNCE A Good Stock To Buy Now? Insider Monkey
Dec-16-20 12:02AM	How Much Of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Do Insiders Own? Simply Wall St.
Nov-09-20 07:00AM	Concert Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire
Nov-06-20 04:01PM	Concert Pharmaceuticals, Inc. (CNCE) Q3 2020 Earnings Call Transcript Motley Fool
Nov-05-20 06:30AM	Concert Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
06:00AM	Concert Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Company Update Business Wire
Nov-03-20 07:00AM	Concert Pharmaceuticals Initiates THRIVE-AA1 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata Business Wire
Nov-01-20 08:57AM	If You Had Bought Concert Pharmaceuticals (NASDAQ:CNCE) Stock A Year Ago, You Could Pocket A 59% Gain Today Simply Wall St.
Oct-29-20 10:00AM	Concert Pharmaceuticals Presents CTP-543 Data from Long-Term Extension Study in Alopecia Areata During Late-Breaking Session at EADV Congress Business Wire
07:00AM	Concert Pharmaceuticals to Report Third Quarter 2020 Financial Results on November 5, 2020 Business Wire
Oct-22-20 07:00AM	Concert Pharmaceuticals Announces Publication on Alopecia Areata Burden of Disease in Journal of Investigative Dermatology Business Wire +5.87%
Oct-13-20 07:00AM	Concert Pharmaceuticals Announces CTP-543 Alopecia Areata Data Selected for Late-Breaker Oral Presentation at 2020 EADV Virtual Congress Business Wire
Sep-29-20 07:00AM	Concert Pharmaceuticals Completes Enrollment in CTP-692 Phase 2 Trial in Patients with Schizophrenia Business Wire
Sep-08-20 07:00AM	Concert Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire
Aug-18-20 06:00AM	Concert Pharmaceuticals to Present at The JMP Securities CNS Forum Business Wire
Aug-12-20 08:06AM	How Does Concert Pharmaceuticals' (NASDAQ:CNCE) CEO Salary Compare to Peers? Simply Wall St.
Aug-06-20 11:05AM	Concert Pharmaceuticals (CNCE) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:00AM	Concert Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Company Update Business Wire
Jul-30-20 12:33PM	Will Concert Pharmaceuticals (CNCE) Report Negative Q2 Earnings? What You Should Know Zacks +6.34%
07:00AM	Concert Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 6, 2020 Business Wire
Jul-08-20 07:00AM	Concert Pharmaceuticals Receives FDA Breakthrough Therapy Designation for CTP-543 for the Treatment of Alopecia Areata Business Wire +5.71%
Jul-06-20 11:44AM	Need To Know: Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Insiders Have Been Buying Shares Simply Wall St. +6.15%
09:30AM	Hedge Fund Sentiment Is Stagnant On Concert Pharmaceuticals Inc (CNCE) Insider Monkey
Jun-30-20 12:00PM	Concert (CNCE) Upgraded to Buy: Here's Why Zacks +5.18%
11:30AM	Is Concert Pharmaceuticals (CNCE) Stock Outpacing Its Medical Peers This Year? Zacks
Jun-24-20 10:39AM	Insider Sells Concert Pharmaceuticals' Shares Benzinga -5.80%
Jun-12-20 04:01PM	Concert Pharmaceuticals Releases Additional Data from Phase 2 Clinical Trial of CTP-543 in Alopecia Areata Business Wire +7.31%
May-26-20 07:00AM	Concert Pharmaceuticals to Webcast Fireside Chat at Jefferies Virtual Global Healthcare Conference Business Wire
May-22-20 08:52AM	How Concert Pharmaceuticals (CNCE) Stock Stands Out in a Strong Industry Zacks
May-12-20 09:14PM	Edited Transcript of CNCE earnings conference call or presentation 30-Apr-20 12:30pm GMT Thomson Reuters StreetEvents -5.37%
07:00AM	Concert Pharmaceuticals to Webcast Presentation at UBS Virtual Healthcare Conference Business Wire
May-01-20 12:30AM	Concert Pharmaceuticals, Inc. (CNCE) Q1 2020 Earnings Call Transcript Motley Fool -16.23%
Apr-30-20 08:45AM	Concert Pharmaceuticals (CNCE) Reports Q1 Loss, Lags Revenue Estimates Zacks -11.99%
07:00AM	Concert Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Update on Clinical Programs Business Wire
Apr-29-20 12:00PM	Concert (CNCE) Moves to Buy: Rationale Behind the Upgrade Zacks +8.21%
Apr-23-20 07:00AM	Concert Pharmaceuticals to Report First Quarter 2020 Financial Results on April 30, 2020 Business Wire
Apr-15-20 08:55AM	Why Concert Pharmaceuticals (CNCE) Stock Might be a Great Pick Zacks -5.87%
Apr-01-20 07:00AM	Concert Pharmaceuticals Announces Plans for CTP-543 Phase 3 Trials in Alopecia Areata Business Wire -11.54%
Mar-26-20 11:54AM	Some Concert Pharmaceuticals (NASDAQ:CNCE) Shareholders Are Down 47% Simply Wall St. +5.13%
Mar-12-20 12:13AM	Edited Transcript of CNCE earnings conference call or presentation 27-Feb-20 1:30pm GMT Thomson Reuters StreetEvents -5.99%
Feb-24-20 07:00AM	Concert Pharmaceuticals Selected for Late-Breaking Oral Presentation of CTP-543 Phase 2 Data in Alopecia Areata at the 2020 American Academy of Dermatology Annual Meeting Business Wire
Feb-20-20 07:00AM	Concert Pharmaceuticals to Report Full Year 2019 Results on February 27, 2020 Business Wire -5.04%
Jan-30-20 04:01PM	Concert Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
Jan-28-20 09:00AM	Concert Pharmaceuticals Announces Pricing of Public Offering Business Wire +9.83%
Jan-27-20 04:02PM	Concert Pharmaceuticals Announces Proposed Public Offering of Common Stock Business Wire -8.61%
04:01PM	Concert Pharmaceuticals Announces Federal Circuit Granted its Motion to Vacate and Remand PTAB Decision Involving CTP-543 Business Wire
Jan-24-20 05:52AM	Should You Be Concerned About Concert Pharmaceuticals, Inc.'s (NASDAQ:CNCE) Historical Volatility? Simply Wall St. -15.00%
Jan-22-20 08:40AM	Concert Pharmaceuticals Announces Notice of Allowance for U.S. Patent Application Related to CTP-543, Lead Candidate for Treatment of Alopecia Areata Business Wire +33.03%
Dec-19-19 04:05PM	Concert Pharmaceuticals Successfully Completes Open Label Trial of CTP-543 in Patients with Alopecia Areata Business Wire
Dec-16-19 05:54AM	We Think Concert Pharmaceuticals (NASDAQ:CNCE) Needs To Drive Business Growth Carefully Simply Wall St.
Dec-13-19 02:18PM	Do Hedge Funds Love Concert Pharmaceuticals Inc (CNCE)? Insider Monkey
Dec-02-19 07:00AM	Concert Pharmaceuticals Initiates CTP-692 Phase 2 Trial in Schizophrenia Business Wire
Nov-25-19 11:21PM	Edited Transcript of CNCE earnings conference call or presentation 7-Nov-19 1:30pm GMT Thomson Reuters StreetEvents
Nov-12-19 07:00AM	Concert Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire +6.63%
Nov-10-19 08:40AM	Should You Worry About Concert Pharmaceuticals, Inc.'s (NASDAQ:CNCE) CEO Salary Level? Simply Wall St.
Nov-07-19 08:15AM	Concert Pharmaceuticals (CNCE) Reports Q3 Loss, Misses Revenue Estimates Zacks
07:00AM	Concert Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Company Update Business Wire
Nov-06-19 07:00AM	Concert Pharmaceuticals to Host KOL Webcast Event Focused on CTP-692 and Schizophrenia Business Wire
Nov-05-19 01:36PM	Concert Pharmaceuticals Inc (CNCE) Is Burning These Hedge Funds Insider Monkey
Oct-31-19 10:35AM	Analysts Estimate Concert Pharmaceuticals (CNCE) to Report a Decline in Earnings: What to Look Out for Zacks
07:00AM	Concert Pharmaceuticals to Report Third Quarter 2019 Financial Results on November 7, 2019 Business Wire
Oct-12-19 03:15AM	Concert Pharmaceuticals Presents Positive Phase 2 Data in Alopecia Areata During Late-Breaker Session at EADV Congress Business Wire
Oct-02-19 07:00AM	Concert Pharmaceuticals to Provide Overview of Clinical Pipeline at Cantor Healthcare Conference Business Wire
Sep-27-19 11:48AM	Concert stock falls 36 percent on Alzheimer's drug trial failure American City Business Journals -36.68%
Sep-23-19 07:00AM	Concert Pharmaceuticals Names Jeffrey Munsie as Chief Legal Officer Business Wire
Sep-19-19 10:32AM	Did You Manage To Avoid Concert Pharmaceuticals's (NASDAQ:CNCE) 20% Share Price Drop? Simply Wall St.
Sep-17-19 07:00AM	Concert Pharmaceuticals Completes Enrollment in Second Open Label Trial of CTP-543 to Evaluate Once-Daily vs. Twice-Daily Dosing in Patients with Alopecia Areata Business Wire
Sep-12-19 07:00AM	Concert Pharmaceuticals Announces CTP-543 Phase 2 Alopecia Areata Data Selected for Late-Breaker Oral Presentation at 2019 EADV Congress Business Wire
Aug-29-19 07:00AM	Concert Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire
Aug-27-19 12:17AM	Edited Transcript of CNCE earnings conference call or presentation 1-Aug-19 12:30pm GMT Thomson Reuters StreetEvents
Aug-16-19 03:10PM	What You Must Know About Concert Pharmaceuticals, Inc.'s (NASDAQ:CNCE) Beta Value Simply Wall St.
Aug-06-19 05:12AM	Concert Pharmaceuticals, Inc. (CNCE) Q2 2019 Earnings Call Transcript Motley Fool
Aug-01-19 09:25AM	Concert Pharmaceuticals (CNCE) Reports Q2 Loss, Misses Revenue Estimates Zacks +8.75%
Jul-25-19 07:00AM	Concert Pharmaceuticals to Report Second Quarter 2019 Financial Results on August 1, 2019 Business Wire
Jul-05-19 03:12PM	Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Insiders Increased Their Holdings Simply Wall St.
Jun-13-19 05:05PM	Concert Pharma's CTP-692 Positive for Schizophrenia in Phase I Zacks +6.47%
Jun-12-19 07:00AM	Concert Pharmaceuticals Reports Positive Results from Phase 1 Studies Evaluating CTP-692 in Healthy Volunteers Business Wire
Jun-05-19 07:00AM	Concert Pharmaceuticals Completes Enrollment in Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia Areata Business Wire
May-28-19 02:13PM	Edited Transcript of CNCE earnings conference call or presentation 2-May-19 12:30pm GMT Thomson Reuters StreetEvents
May-16-19 07:00AM	Concert Pharmaceuticals Announces Initiation of New Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia Areata Business Wire
May-14-19 07:00AM	Concert Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire
May-07-19 01:51PM	Why Concert Pharmaceuticals, Inc.'s (NASDAQ:CNCE) CEO Pay Matters To You Simply Wall St.
May-02-19 11:52AM	Concert Pharmaceuticals, Inc. (CNCE) Q1 2019 Earnings Call Transcript Motley Fool
08:01AM	Concert: 1Q Earnings Snapshot Associated Press
07:00AM	Concert Pharmaceuticals Reports First Quarter 2019 Financial Results Business Wire
Apr-29-19 07:00AM	Concert Pharmaceuticals Names Jesper Høiland to its Board of Directors Business Wire
Apr-25-19 10:34AM	Earnings Preview: Concert Pharmaceuticals (CNCE) Q1 Earnings Expected to Decline Zacks
07:00AM	Concert Pharmaceuticals to Report First Quarter 2019 Financial Results on May 2, 2019 Business Wire
Apr-11-19 09:46AM	Concert Pharma Initiates Early-Stage Schizophrenia Study Zacks
07:00AM	Concert Pharmaceuticals to Present CTP-543 Phase 2 Interim Data in Alopecia Areata at 2019 World Congress for Hair Research Annual Meeting Business Wire
Apr-10-19 06:30AM	Concert Pharmaceuticals Initiates Phase 1 Multiple-Ascending Dose Trial of CTP-692 as an Adjunctive Treatment for Schizophrenia Business Wire

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for the treatment of autoimmune and central nervous system disorders. Its product candidates include CTP-543, which is in Phase III clinical trials for the treatment of alopecia areata; CTP-692, a selective deuterium-modified analog of the endogenous amino acid and D-serine that is in Phase II trials for the treatment of schizophrenia; and AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease. The company has strategic collaborations with Avanir Pharmaceuticals, Inc.; Cipla Technologies; Processa Pharmaceuticals; and Jazz Pharmaceuticals, Inc. Concert Pharmaceuticals was founded in 2006 and is headquartered in Lexington, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Tung Roger D	Chief Executive Officer	Feb 17	Sale	7.20	13,480	97,056	808,578	Feb 17 09:42 PM
Stuart Nancy	Chief Operating Officer	Feb 16	Sale	7.32	6,049	44,279	173,280	Feb 17 09:34 PM
Munsie Jeffrey A	Chief Legal Officer	Feb 16	Sale	7.32	3,763	27,545	46,153	Feb 17 09:31 PM
Cassella James V	Chief Development Officer	Feb 16	Sale	7.32	3,763	27,545	94,064	Feb 17 09:27 PM
Becker Marc A.	Chief Financial Officer	Feb 16	Sale	7.32	3,763	27,545	71,371	Feb 17 09:21 PM
HUTT PETER BARTON	Director	Aug 31	Option Exercise	3.79	3,539	13,413	7,963	Sep 01 04:01 PM
Cassella James V	Chief Development Officer	Aug 17	Sale	10.37	4,354	45,151	76,127	Aug 19 05:44 PM
Becker Marc A.	Chief Financial Officer	Aug 17	Sale	10.24	2,875	29,440	53,434	Aug 19 05:43 PM
Stuart Nancy	Chief Operating Officer	Jun 22	Option Exercise	3.79	21,238	80,492	167,924	Jun 24 09:02 AM
Stuart Nancy	Chief Operating Officer	Jun 22	Sale	11.34	10,295	116,694	157,629	Jun 24 09:02 AM
Tung Roger D	Chief Executive Officer	Mar 13	Option Exercise	3.79	14,601	55,338	752,758	Mar 16 07:23 AM
Auchincloss Thomas G	Director	Mar 12	Buy	8.52	1,500	12,773	6,500	Mar 13 12:19 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience